Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5746540 | 0.81 | TSHR (0.48) | SLC6A3SLC6A4LMNATSHRALDH1A1 | |
| SCHEMBL10700176 | 0.81 | NPC1 (0.45) | SLC6A3LMNAALDH1A1HSD17B10KDM4E | |
| SCHEMBL1098615 | 0.79 | TSHR (0.50) | SLC6A3SLC6A4LMNATSHRALDH1A1 | |
| SCHEMBL7406380 | 0.79 | LMNA (0.55) | SLC6A3SLC6A4LMNATSHRALDH1A1 | |
| SCHEMBL670604 | 0.79 | LMNA (0.50) | SLC6A3SLC6A4LMNATSHRALDH1A1 | |
| SCHEMBL14661019 | 0.79 | CES2 (0.35) | SLC6A3SLC6A4LMNATSHRALDH1A1 | |
| SCHEMBL10652894 | 0.78 | TSHR (0.48) | SLC6A3SLC6A4LMNATSHRALDH1A1 | |
| SCHEMBL5106840 | 0.78 | LMNA (0.48) | SLC6A3SLC6A4LMNATSHRALDH1A1 | |
| SCHEMBL20448911 | 0.78 | GAA (0.47) | SLC6A3SLC6A4ALDH1A1POLBSLC6A2 | |
| SCHEMBL7006875 | 0.78 | ALDH1A1 (0.56) | SLC6A3LMNATSHRALDH1A1CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113416229-A | Cytotoxic and antimitotic compounds, and methods of use thereof | 酵活有限公司 | 2021-09-21 | — | — | CN | claimed |
| US-10675355-B2 | VAR2CSA-drug conjugates | VAR2 PHARMACEUTICALS APS (DK) | 2020-06-09 | — | — | US | claimed |
| US-20190345254-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS INC (CA) | 2019-11-14 | — | — | US | claimed |
| US-10414822-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. (CA) | 2019-09-17 | — | — | US | claimed |
| US-20180208667-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2018-07-26 | — | — | US | claimed |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2018-05-03 | — | — | US | claimed |
| US-9879086-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. (CA) | 2018-01-30 | — | — | US | claimed |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-08-31 | — | — | US | claimed |
| EP-3194421-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | Zymeworks, Inc. (CA) | 2017-07-26 | — | — | EP | claimed |
| EP-3087091-A1 | VAR2CSA-DRUG CONJUGATES | Zymeworks Inc. (CA) | 2016-11-02 | — | — | EP | claimed |
| WO-2016041082-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CDRD Ventures, Inc. (CA) | 2016-03-24 | — | — | WO | claimed |
| US-20160075735-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2016-03-17 | — | — | US | claimed |
| WO-2015095952-A1 | VAR2CSA-DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | claimed |
| US-20230317700-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-10-05 | — | — | US | disclosed |
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS BC INC. (CA) | 2023-08-24 | — | — | US | disclosed |
| US-11591405-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2023-02-28 | — | — | US | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2029570-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | SLC6A3 597/4885SLC6A4 747/4885LMNA 1797/4885 |
| US-20160075735-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | SLC6A3 4297/4885SLC6A4 4387/4885LMNA 218/4885 |
| US-20190345254-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | SLC6A3 4297/4885SLC6A4 4387/4885LMNA 218/4885 |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | SLC6A3 261/4885SLC6A4 1100/4885LMNA 3260/4885 |
| US-10675355-B2 | VAR2CSA-drug conjugates | VARS1, GUSB, VAV1 | SLC6A3 261/4885SLC6A4 1100/4885LMNA 3260/4885 |
| US-20180117163-A9 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | SLC6A3 261/4885SLC6A4 1100/4885LMNA 3260/4885 |
| US-11591405-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | SLC6A3 4297/4885SLC6A4 4387/4885LMNA 218/4885 |
| US-10414822-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | SLC6A3 4297/4885SLC6A4 4387/4885LMNA 218/4885 |
| US-20180208667-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | SLC6A3 4297/4885SLC6A4 4387/4885LMNA 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.